CTLA4 and neoplasm: Clinical studies demonstrate that CD4 T cells with anti-tumor reactivity can mediate their effects via direct cytotoxicity against tumor targets [177,309,312], and by broadening the CD8 T-cell response in the context of immunotherapy, such as with anti-CTLA-4 antibodies [214].